GB815969A - Therapeutic compositions containing hexyl-3:7-dimethylxanthine - Google Patents
Therapeutic compositions containing hexyl-3:7-dimethylxanthineInfo
- Publication number
- GB815969A GB815969A GB6103/58A GB610358A GB815969A GB 815969 A GB815969 A GB 815969A GB 6103/58 A GB6103/58 A GB 6103/58A GB 610358 A GB610358 A GB 610358A GB 815969 A GB815969 A GB 815969A
- Authority
- GB
- United Kingdom
- Prior art keywords
- salt
- nicotinic acid
- dimethylxanthine
- mgms
- hexyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
A pharmaceutical preparation for the treatment of cerebral sclerosis comprises 1-hexyl-3,7-dimethylxanthine together with nicotinic acid or a non-toxic salt thereof, for example an alkali metal or ammonium salt, for instance in the ratio by weight of from 1 : 1 to 10 : 1, and preferably 4 : 1, of the xanthine derivative to the nicotinic acid or salt. The composition may be in the form of tablets, capsules, cachets, syrups, and suspensions adapted for oral administration, such unit dosage forms containing from 50 to 500 mgms. of the xanthine derivative together with suitable amounts of the nicotinic acid or salt. An example of such a unit dose is about 200 mgms of 1-hexyl-3,7-dimethyl xanthine and about 50 mgms. of the nicotinic acid or salt.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US815969XA | 1957-04-02 | 1957-04-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GB815969A true GB815969A (en) | 1959-07-01 |
Family
ID=22165143
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB6103/58A Expired GB815969A (en) | 1957-04-02 | 1958-02-25 | Therapeutic compositions containing hexyl-3:7-dimethylxanthine |
Country Status (1)
| Country | Link |
|---|---|
| GB (1) | GB815969A (en) |
-
1958
- 1958-02-25 GB GB6103/58A patent/GB815969A/en not_active Expired
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES424533A1 (en) | Slow release pharmaceutical compositions | |
| GB824908A (en) | Improvements in or relating to triazine derivatives | |
| US3777020A (en) | Psoriasis treatment with mycophenolic acid | |
| GB815969A (en) | Therapeutic compositions containing hexyl-3:7-dimethylxanthine | |
| US2953493A (en) | Therapeutic compositions containing 1-hexyl 3, 7-dimethylxanthine and nicotinates | |
| GB1464467A (en) | Pharmaceutical composition for the treatment of coronary | |
| Pecknold et al. | Lack of indication for use of antiparkinson medication: A follow-up study. | |
| GB950162A (en) | Medicines for the treatment of hepatic disorders | |
| US3060095A (en) | Method of administering vitamin b | |
| US3577549A (en) | Treatment of pain or inflammation with p-benzoyl-phenylacetic acid or o-benzoyl-phenylacetic acid | |
| GB791644A (en) | Barbiturate pharmaceutical preparations | |
| IE35419L (en) | Pharmaceutical composition containing cyclobenzaprine | |
| US2850429A (en) | Liquid vitamin preparation | |
| GB876320A (en) | Pharmaceutical compositions containing d-3:5-diiodothyronine | |
| GB1300486A (en) | Compositions for the treatment of respiratory ailments in man | |
| GB1157662A (en) | Improvements in or relating to Pharmaceutical Compositions | |
| GB911179A (en) | Hypnotic and tranquilizing compositions comprising 4, 6-dimethyl-3-pyridazone | |
| Bateman et al. | The effect of metoclopramide and haloperidol on tardive dyskinesia [proceedings] | |
| GB1153014A (en) | Improvements in or relating to An Oral Dose for the Treatment of Tuberculosis | |
| GB1187873A (en) | Pharmaceutical Compositions Comprising a Cardiac Glycoside. | |
| GB1062899A (en) | Improvements in and relating to therapeutic compositions | |
| GB1142757A (en) | Therapeutic compositions | |
| GB976096A (en) | Pharmaceutical compositions | |
| GB942981A (en) | Therapeutic composition having a hypotensive action and containing a mixture of 3-hydrazino 6-carbamoyl pyridazine and reserpine | |
| GB908634A (en) | Pharmaceutical compositions containing pararosaniline or derivatives thereof |